home / stock / bbio / bbio news

BBIO News and Press, BridgeBio Pharma Inc. From 10/29/25

Stock Information
Company Name: BridgeBio Pharma Inc.
Stock Symbol: BBIO
Market: NASDAQ
Website: bridgebio.com
Menu
BBIO BBIO Quote BBIO Short BBIO News BBIO Articles BBIO Message Board
Get BBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
BBIO - BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue

2025-10-29 22:57:08 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript BridgeBio Pharma, Inc. 2025 Q3 - Results - Earnings Call Presentation BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in AD...
BBIO - BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript

2025-10-29 22:56:25 ET BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript

BBIO - BridgeBio Pharma GAAP EPS of -$0.95 misses by $0.06, revenue of $120.7M beats by $14.65M

2025-10-29 16:04:15 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study - Slid...

BBIO - BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

PALO ALTO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the third quarter ended September 3...
BBIO - BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript

2025-10-29 12:06:35 ET BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study October 29, 2025 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Discusses Positive Ph...

BBIO - BBIO Price Target Alert: $90.00. Issued by H.C. Wainwright

2025-10-29 10:22:37 ET from H.C. Wainwright issued a price target of $90.00 for BBIO on 2025-10-29 13:28:45. The adjusted price target was set to $90.00. At the time of the announcement, BBIO was trading at $65.7338. The overall price target consensus is at $72.25 with h...

BBIO - BridgeBio succeeds in late-stage encaleret study

2025-10-29 10:05:22 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Li...
BBIO - Here are the major earnings after the close Wednesday

2025-10-29 10:00:00 ET Major earnings expected after the bell on Wednesday include: Microsoft Corporation ( MSFT ) Alphabet ( GOOG ) Meta Platforms ( META ) Starbucks Corporation ( SBUX ) Teladoc Health ( TDOC ) Read the full article on Seek...

BBIO - Expected US Company Earnings on Wednesday, October 29th, 2025

Amerigo Resources Ltd (ARREF) is expected to report $0.06 for Q3 2025 Bausch + Lomb Corporation (BLCO) is expected to report $0.16 for Q3 2025 Hayward Holdings Inc. (HAYW) is expected to report $0.11 for Q3 2025 Automatic Data Processing Inc. (ADP) is expected to report $2.44 for Q1 2...

BBIO - BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline results of the autosomal dominant hy...
Previous 10 Next 10